P
PQ Bypass
PQ Bypass is a medtech company advancing the treatment of long-segment peripheral artery disease
About PQ Bypass
PQ Bypass is a medical device startup pioneering minimally invasive treatments for Peripheral Artery Disease (PAD), specifically targeting the superficial femoral artery (SFA) disease. The company operates in the healthcare sector, focusing on developing advanced technologies such as the TORUS Stent Graft, PQ Snare, and PQ Crossing Device. These innovations are designed by physicians for physicians and their patients, aiming to improve the safety and effectiveness of PAD treatments. PQ Bypass is currently enrolling patients in two major clinical trials: the TORUS 2 IDE Clinical Study and the DETOUR 2 IDE Clinical Study. These trials are multi-center, international investigations evaluating the company's stent graft systems. The business model revolves around the development, clinical testing, and eventual commercialization of these medical devices. Revenue is generated through the sale of these devices to healthcare providers once they receive regulatory approval. The company primarily serves hospitals, clinics, and medical professionals specializing in vascular surgery and interventional cardiology.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2009
- Headquarters
- Sunnyvale, United States
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 26.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Surgery, Cardiology and cardiovascular, Catheters, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2021 | $0 | — | Endologix | — |
| LATE VCOther financing | Jan 2019 | $60M | $240M | Seroba Life Sciences · MedTech VP · Deerfield | ↗ |
Growth signals
Latest recorded traffic for PQ Bypass is 710 monthly website visits, down 35.5% over the last three months. PQ Bypass's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Seroba Kernel
Series B and later3 investors entered at this stage
Deerfield
Seroba Life Sciences
MedTech VP
Other known investors1 additional known investor
Endologix
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about PQ Bypass on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PQ Bypass’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.